An Open-Label, Multi-Center, Randomized Phase 1b/2 Study Of PF-05212384 Plus 5-Fluorouracil-Leucovorin-Irinotecan (FOLFIRI) Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer
Phase of Trial: Phase I/II
Latest Information Update: 23 Aug 2016
Price : $35 *
At a glance
- Drugs Gedatolisib (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 15 Oct 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 18 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.